Helen Torley Sells 20,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. This represents a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Friday, September 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $107.24, for a total transaction of $2,144,800.00.
• On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00.
• On Wednesday, July 8th, Helen Torley sold 1,923 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $79.77, for a total transaction of $153,397.71.

Halozyme Therapeutics Stock Performance

HALO stock traded up $0.20 during mid-day trading on Friday, hitting $107.20. 861,533 shares of the company were exchanged, compared to its average volume of 1,560,954. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $111.15. The stock has a market capitalization of $12.17 billion, a PE ratio of 32.00, a price-to-earnings-growth ratio of 0.41 and a beta of 0.88. The business has a 50 day simple moving average of $93.73 and a 200-day simple moving average of $76.97. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. HC Wainwright restated a “buy” rating and set a $115.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, September 2nd. TD Cowen raised their target price on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Finally, Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $91.20.

Institutional Investors Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Talon Private Wealth LLC acquired a new stake in Halozyme Therapeutics during the second quarter worth about $839,000. Sequoia Financial Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $359,000. Tidal Investments LLC lifted its holdings in shares of Halozyme Therapeutics by 13.5% during the 2nd quarter. Tidal Investments LLC now owns 190,305 shares of the biopharmaceutical company’s stock worth $14,895,000 after acquiring an additional 22,707 shares during the period. WINTON GROUP Ltd lifted its holdings in shares of Halozyme Therapeutics by 704.6% during the 2nd quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company’s stock worth $4,723,000 after acquiring an additional 52,848 shares during the period. Finally, Engineers Gate Manager LP boosted its position in shares of Halozyme Therapeutics by 6.7% during the 2nd quarter. Engineers Gate Manager LP now owns 46,172 shares of the biopharmaceutical company’s stock worth $3,614,000 after acquiring an additional 2,889 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.